Highlights from the FDA-ASCO workshop on dose optimization for oncology drugs
The FDA-ASCO (American Society of Clinical Oncology) workshop on oncology dose optimization (3-5 May 2022)…
CertaraJuly 8, 2022
Using Clinical Pharmacology & Pharmacometrics to Accelerate Cell Therapy Development: A Patient’s CAR-T Journey
Cell therapies aim to treat, prevent, or potentially cure diseases. They are a relatively new…
CertaraJuly 8, 2022
CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response.
See how CYP2A6 affects exposure; GABRA2 predicts heart‑rate abnormalities using Phoenix NLME.
CertaraJuly 7, 2022
Why FDA’s new guidance on circulating tumor DNA is critical for oncology early clinical drug development
2022 is shaping up to be the “year of the guidance” as the FDA has…
CertaraJuly 1, 2022
A study to explore the appropriateness of dosing regimen of vancomycin in critically ill patients in a tertiary care unit of India
Learn how weight and creatinine clearance improve prediction; standard dosing insufficient using Phoenix NLME.
CertaraJune 30, 2022
Axendia: Improving Healthcare Outcomes by Rewarding Value, NOT Cost
This research examines the use of value-based communications to support the transition to fee-for-outcomes models…
CertaraJune 28, 2022
Certara’s Simcyp Discovery Demo
View this software demo by Dr. Hannah Jones to learn about how Simcyp Discovery provides…
CertaraJune 28, 2022
Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers.
Find out how co‑administration shows BE‑range PK for both drugs using Phoenix WinNonlin.
CertaraJune 28, 2022
Utilizing Pharmacokinetic and Pharmacodynamic Modeling & Simulation Technologies for Anesthesiology and Pain Medicine
Today, we are interviewing Professor Gyujeong Noh from Anesthesiology and Pain Medicine/Clinical Pharmacology and Therapeutics…
CertaraJune 17, 2022
